CanFite Biopharma (CANF)
(Real Time Quote from BATS)
$2.46 USD
-0.11 (-4.28%)
Updated Jun 6, 2024 11:43 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 161 - 180 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Better Late than Never-CF101 Shows Activity at 32 Weeks; Raising PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Building Cautious Optimism on Psoriasis Analyses; Target to $3.30
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
4Q14 Update-Phase 2/3 Psoriasis Trial Misses Primary Endpoint; Lowering PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Psoriasis Misses; Future of CF101 Unclear; Downgrade to Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Canadian Partnership for CF101; Psoriasis Data Next; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Important Building Block in Place; Psoriasis Data Soon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
CF101 PhII/III Complete, Top Line Data by 1Q15 End; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Arousing CF602 Preclinical Data-2015 Begins with Development Thrust
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Psoriasis Data in 1Q15; Tweaking Model on Raise; Target Lowered to $20
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
1st Patient Dosed in ''102 PhII; PhII/III Psoriasis Data Expected in 1Q15
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
3Q14 Update - Cash Runway Extended for ?Fite? to the Finish Line - Data in 1Q15
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R